This is a federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Biocryst Pharmaceuticals Inc. The contract is a definitive, cost-plus-fixed-fee contract with a ceiling value of $11,911,993.55 and an ultimate completion date of May 31, 2021. The contract does not have a set-aside designation.
Biocryst Pharmaceuticals is a biotechnology company that specializes in developing small molecule drugs for rare diseases. The contract is for the company's pharmaceutical products, including ORLADEYO (berotralstat) for hereditary angioedema and RAPIVAB (peramivir) for influenza treatment. Biocryst has multiple federal contract vehicles, including a Federal Supply Schedule 61-IB contract and Blanket Purchase Agreements with the Department of Veterans Affairs, which facilitate streamlined ordering of its pharmaceutical products for various government customers.
Generated 8/14/24, 9:15 AM